Rockefeller Capital Management
BCYC

Rockefeller Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Rockefeller Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$23 – 4743
2026
Q1 		$23 Hold
5
– – ﹤0.01% 4661
2025
Q4 		$35 Hold
5
– – ﹤0.01% 4649
2025
Q3 		$39 Buy
+5
New +$38 ﹤0.01% 4401
2023
Q1 		– Sell
-213
Closed -$6K – 2156
2022
Q4 		$6K Hold
213
– – ﹤0.01% 3253
2022
Q3 		$4K Hold
213
– – ﹤0.01% 3381
2022
Q2 		$3K Buy
213
+48
+29% +$1.01K ﹤0.01% 3620
2022
Q1 		$7K Hold
165
– – ﹤0.01% 3198
2021
Q4 		$10K Sell
165
-181
-52% -$9.99K ﹤0.01% 2965
2021
Q3 		$14K Buy
+346
New +$12.1K ﹤0.01% 2726

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rockefeller Capital Management's BCYC Position: Q2 2026 in Review

Rockefeller Capital Management sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 5 shares — an estimated $23 sold.

Rockefeller Capital Management first reported a position in BCYC in Q3 2021 and held it in 9 quarters. The position peaked at $14K in Q3 2021. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Rockefeller Capital Management reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 5 Bicycle Therapeutics shares in Q2 2026, an estimated $23.
  • Rockefeller Capital Management first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 9 quarters.
  • Rockefeller Capital Management's Bicycle Therapeutics position peaked at $14K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.